Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 133 PK in Hepatic Impairment
NCT07428525Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of maridebart cafraglutide in obesity (4 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration at 120 days, Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration at 120 days and 1 more. Started Mar 2025; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07428525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428525.